HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis

Chinese Journal of Oncology

Volumn 33, Issue 9, 2011, Pages 671-675

  Wang, Yan ^a   Xu, Jian Ming ^a   Liu, Jian Zhi ^a   Lin, Li ^a   Ge, Fei Jiao ^a   Li, Shan Shan ^a   Liu, Lie Jun ^a   Zhao, Chuan Hua ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Drug therapy; Gastric neoplasms; Human epidermal growth fator receptor 2; Pathology; Prognosis

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CHINESE; CLINICAL FEATURE; CORRELATION ANALYSIS; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH CANCER; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 80155181163     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2011.09.007     Document Type: Article

References (10)

1. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric cancer or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376:687-697.
2. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 2008, 19:1523-1529.
3. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol, 2008, 26:1435-1442.
4. Okines AF, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol, 2009, 20:1529-1534.
5. Allgayer H, Babic R, Gruetzner KU, et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol, 2000, 18:2201-2209. (Pubitemid 30350211)
6. Tanner M, Hollmén M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol, 2005, 16:273-278. (Pubitemid 40309309)
7. Li XL, Yi SQ, Xu JM, et al. The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-Fluorouracil or cisplatin on gastric cancer cell lines. Cancer Invest, 2010, 28:1038-1047.